EBV reactivation plus immunotherapy for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Infections, Mouth & dental clinical trials.
This trial tests a combination therapy that first wakes up the Epstein-Barr virus (EBV) in cancer cells and then uses an immune-boosting drug (PD-1 antibody) to help your body attack them. It is for people whose nasopharyngeal cancer has come back or spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed nasopharyngeal cancer that has returned or spread, with a positive test for EBV in the tumor.
- You must be 18 to 75 years old and in generally good health (able to care for yourself and up and about).
- Your blood tests must show EBV DNA is present, and your organ function (kidney, liver, blood counts) must be within acceptable ranges.
- You cannot have had certain other cancer treatments (radiation, other immunotherapies, or EBV-specific drugs) within the past 28 days.
- You must not have serious bleeding problems, active infections like tuberculosis, or untreated hepatitis B or C.
- You cannot be pregnant or breastfeeding, and must agree to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
This trial tests whether giving chemotherapy plus immunotherapy (pembrolizumab) before and after surgery can help people whose nasopharyngeal cancer has come back in the same area (locally recurrent). The goal is to see if this approach improves outcomes.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests if an immunotherapy drug (adebrelimab) can help people with advanced nasopharyngeal cancer whose Epstein-Barr virus (EBV) DNA levels stay high or stable after initial chemotherapy. It aims to see if this personalized approach improves outcomes.
This trial tests a combination of a new targeted cancer drug (becotatug vedotin), an immunotherapy (PD-1 blockade), and chemoradiotherapy for newly diagnosed advanced nasopharyngeal cancer that has spread to nearby lymph nodes. The goal is to improve outcomes for patients with this aggressive cancer type.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.